The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22815652.
- Also identified by DOI 10.1371/journal.pmed.1001240 and PMC identifier 3398965.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Using the SWITCHMRK and MONET trials as examples, Andrew Carr and colleagues question the ethics and motives of switch or simplification trials of anti-retroviral therapy.
Medical subject headings
- Antiretroviral Therapy, Highly Active
- Clinical Trials as Topic